Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis : results of a 12-week, phase II, dose-finding study.

Alten, Rieke;Gomez-Reino, Juan;Durez, Patrick;Beaulieu, Andre;Kellner, Herbert;et.al.
(2011) BMC Musculoskeletal Disorders — Vol. 12, p. 153 (2011)

Files

pdfdocument.pdf
  • Open Access
  • Adobe PDF
  • 1.7 MB
Download

Details

Authors
  • Alten, Rieke
    Author
  • Gomez-Reino, Juan
    Author
  • Durez, PatrickUCLouvain
    Author
  • Beaulieu, Andre
    Author
  • Kellner, Herbert
    Author
Show more
Abstract
Canakinumab is a fully human anti-interleukin IL-1beta monoclonal antibody, being investigated for the treatment of rheumatoid arthritis (RA). This multicenter, phase II, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study investigated the efficacy and safety of canakinumab in patients with active RA despite ongoing therapy at stable doses of methotrexate.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Alten, R., Gomez-Reino, J., Durez, P., Beaulieu, A., Sebba, A., Krammer, G., Preiss, R., Arulmani, U., Widmer, A., Gitton, X., & Kellner, H. (2011). Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis : results of a 12-week, phase II, dose-finding study. BMC Musculoskeletal Disorders, 12, 153. https://doi.org/10.1186/1471-2474-12-153 (Original work published 2011)